Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access
Terminated
This is a multi-center clinical study in subjects requiring arteriovenous grafts in the upper extremity for hemodialysis access. All subjects will provide informed consent before undergoing any study procedures. The study will consist of multiple subject visits and telephone contacts during the 52 week study period. During the study period subjects must also maintain an appropriate hemodialysis schedule. IDE Number: G060250
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2011
Locations: Ladenheim, Inc., Fresno, California +6 locations
Conditions: Kidney Diseases, ESRD
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California +1 locations
Conditions: Lung Cancer
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Completed
The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2010
Locations: Pfizer Investigational Site, Los Angeles, California
Conditions: Non-small Cell Lung Cancer
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Completed
The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC). The safety of this combination will also be evaluated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2010
Locations: ImClone Investigational Site, Los Angeles, California +1 locations
Conditions: Non-small Cell Lung Cancer
Phase II Study in Patients With Operable Breast Cancer
Unknown
The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and trastuzumab in patients with operable breast cancer. Patients will be treated with the combination for 18 weeks, followed by surgery.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
01/14/2010
Locations: Providence St. Joseph Medical Hospital, Burbank, California +2 locations
Conditions: Breast Cancer
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
Completed
RATIONALE: Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SU5416 with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining SU5416 and paclitaxel in treating patients who have advanced cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2010
Locations: Cancer Center and Beckman Research Institute, City of Hope, Duarte, California +2 locations
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of paclitaxel with or without PSC 833 in treating patients with metastatic breast cancer.
Gender:
ALL
Ages:
All
Trial Updated:
01/04/2010
Locations: Beckman Research Institute, City of Hope, Duarte, California +2 locations
Conditions: Breast Cancer
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2009
Locations: Pfizer Investigational Site, Fountain Valley, California +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
CPG 7909 Injection in Non-Small Cell Lung Cancer
Completed
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every ot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2009
Locations: Office of Ronald Yanagihara, Gilroy, California +2 locations
Conditions: Carcinoma, Non-Small Cell Lung
Chemotherapy in Treating Patients With Metastatic Kidney Cancer
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have locally advanced, metastatic, or unresectable kidney cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
Conditions: Kidney Cancer